Abstract
The post genome era has ushered us into therapeutic target discovery empowering us to mine the genome using rational approaches. Numerous cancer targets have emerged from the genome project for diagnostics, therapeutics and response to therapy prediction. Among thousands of genes predicted in the human genome, nearly half of them remain uncharacterized. Considerable attention in the last decade has focused on the well-characterized known genes. However, the future of cancer target discovery resides in the uncharacterized or novel genes called the dark matter of the human genome. Realizing the importance of this vast untapped potential, recently the US National Cancer Institute announced a new initiative called "Illuminating the Dark Matter of the Genome for Druggability". This area of cancer research albeit exciting, remains a challenge due to the lack of adequate information about the uncharacterized genes. Amongst the plethora of bioinformatics tools and databases, a streamlined approach remains elusive. In this review, we present a simplified approach to mine directly the cancer proteome for rapid target discovery. Using such an approach, we have created a database of uncharacterized cancer genes and have shown the biomarker and drug target potential for an uncharacterized protein, C1ORF87, as a putative solid tumor target. In view of this protein's association with carcinomas, the C1ORF87 is termed as Carcinoma-Related EF-Hand (CREF) gene. The approaches discussed in this review should aid in lighting the dark matter of the human cancer proteome.
Keywords: Post genome, druggable genes, uncharacterized genes, C1ORF87, CREF gene.
Current Cancer Therapy Reviews
Title:Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Volume: 9 Issue: 4
Author(s): Ana Paula Delgado, Pamela Brandao, Sheilin Hamid and Ramaswamy Narayanan
Affiliation:
Keywords: Post genome, druggable genes, uncharacterized genes, C1ORF87, CREF gene.
Abstract: The post genome era has ushered us into therapeutic target discovery empowering us to mine the genome using rational approaches. Numerous cancer targets have emerged from the genome project for diagnostics, therapeutics and response to therapy prediction. Among thousands of genes predicted in the human genome, nearly half of them remain uncharacterized. Considerable attention in the last decade has focused on the well-characterized known genes. However, the future of cancer target discovery resides in the uncharacterized or novel genes called the dark matter of the human genome. Realizing the importance of this vast untapped potential, recently the US National Cancer Institute announced a new initiative called "Illuminating the Dark Matter of the Genome for Druggability". This area of cancer research albeit exciting, remains a challenge due to the lack of adequate information about the uncharacterized genes. Amongst the plethora of bioinformatics tools and databases, a streamlined approach remains elusive. In this review, we present a simplified approach to mine directly the cancer proteome for rapid target discovery. Using such an approach, we have created a database of uncharacterized cancer genes and have shown the biomarker and drug target potential for an uncharacterized protein, C1ORF87, as a putative solid tumor target. In view of this protein's association with carcinomas, the C1ORF87 is termed as Carcinoma-Related EF-Hand (CREF) gene. The approaches discussed in this review should aid in lighting the dark matter of the human cancer proteome.
Export Options
About this article
Cite this article as:
Paula Delgado Ana, Brandao Pamela, Hamid Sheilin and Narayanan Ramaswamy, Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/1573394710666140313003905
DOI https://dx.doi.org/10.2174/1573394710666140313003905 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Cell Compatibility of an Eposimal Vector Mediated by the Characteristic Motifs of Matrix Attachment Regions
Current Gene Therapy Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Inhibition of Human Aromatase by Myosmine
Drug Metabolism Letters Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Undressing the Fungal Cell Wall/Cell Membrane - the Antifungal Drug Targets
Current Pharmaceutical Design Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Biomarkers TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews The Diagnostic Utility of Pleural Fluid Tests in Clinical Practice
Current Respiratory Medicine Reviews Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance
Anti-Cancer Agents in Medicinal Chemistry A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets